|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.
Roche’s (RHHBY) Diagnostics division comprises tissue diagnostics, molecular diagnostics, diabetes care, and centralized and point-of-care solutions. Roche’s Diagnostics division grew 5.0% year-over-year to reach ~2.9 billion Swiss francs.
In 1Q18, Valeant Pharmaceuticals’ (VRX) subsidiary, Bausch + Lomb, generated revenues of $1.10 billion compared to $1.13 billion in 1Q17, which reflected an ~3.0% decline on a year-over-year (or YoY) basis. In 1Q18, Bausch + Lomb witnessed 2.0% organic growth compared to 1Q17.
Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.
Allergan (AGN) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues, reporting EPS of $3.74 on revenues of $3.7 billion during 1Q18. Analysts expect Allergan’s top line to fall 3.3% to ~$3.9 billion in 2Q18. Its earnings per share are expected to reach $4.03 in 2Q18. The chart below shows analysts’ recommendations over the last 12 months.
Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.
GlaxoSmithKline beat Wall Street Analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. It reported EPS of 24.60 pence on revenues of 7.22 billion pounds, compared to analysts’ estimated EPS of 24.21 pence at revenues of 7.20 billion pounds.
Abbott Laboratories (ABT) is a developer and manufacturer of a broad and diversified line of healthcare products. Its business segments include pharmaceutical products, diagnostic products, nutritional products, and cardiovascular and neuromodulation products.
Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.
Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.
Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.
Shares of Abbott Laboratories dipped early Wednesday — despite its broad first-quarter beat — on pharmaceutical sales that lagged Wall Street's expectations by nearly 4%.
On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.
On November 20, 2017, Abbott Laboratories (ABT) stock closed at $55.3. The company reported its 52-week high of $56.7 on October 23, 2017.
During its 3Q17 earnings release on October 18, 2017, Abbott Laboratories (ABT) provided an updated guidance for fiscal 2017 and 4Q17.
The 3Q17 EPS estimate for Abbott Laboratories is $0.65. The company has provided an EPS guidance range of $0.64–$0.66 for 3Q17.
Analysts expect Abbott Laboratories to report 3Q17 revenues of ~$6.7 billion, representing a YoY (year-over-year) growth of ~26.7%.
On August 30, ABT announced the regulatory approval for its dydrogesterone oral medication in Russia and the Netherlands for invitro fertilization treatment.
On September 22, 2017, Abbott Laboratories (ABT) announced the FDA approval of the MR-conditional labeling for its Ellipse ICD.